Needham & Company Starts ISIS Pharmaceuticals (ISIS) at Buy; Looking Beyond Kynamro at Significant Pipeline Value

Needham & Company initiates coverage on ISIS Pharmaceuticals (NASDAQ: ISIS) with a Buy. PT $14.00.

Analyst, Chad Messer, said, "Most investors remained focused on the expected launch of Kynamro in both the U.S. and Europe around the end of the year, but we believe ISIS’ deep pipeline of 26 clinical stage antisense drugs represents the real long term value creator. ISIS and its partners are working to launch 5 additional drugs with substantial market opportunity in the next 5 years while continuing to bring new programs into the clinic. ISIS stands to receive significant economics from most of these programs and retains 100% ownership of many of them forming the basis for additional near term value driving partnerships."

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $9.41 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Needham Starts Viavi Solutions (VIAV) at Hold
• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
• Morgan Stanley Assumes Harley-Davidson (HOG) at Overweight, 'Freshly Tuned Up with Open Road Ahead'